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Abstract The objective of the study was to analyze the
prognostic factors of radiographic progression in a series of
patients with early rheumatoid arthritis (RA) after 2 years
of therapy with a structured algorithm using disease-
modifying antirheumatic drugs (DMARDs) and very low
doses of oral glucocorticoids. One hundred and five
patients (81% female) with early RA (disease duration
<2 years) treated with the same therapeutic protocol using
gold salts and methotrexate in a step-up strategy, together
with methylprednisolone (4 mg/day), were followed up for
2 years. The outcome variable was radiographic progres-
sion after 2 years of DMARD therapy using the modified
Larsen method. Clinical, biological, immunogenetic, and
radiographic data were analyzed at study entry and after 1
and 2 years of follow-up. Radiographic progression
(increase of four or more units in the Larsen score) was
observed in 32% of patients after 2 years of follow-up. The
percentage of erosive disease increased from 18.3% at
baseline to 28.9% at 12 months and 44.6% at 24 months, in
spite of a significant improvement in disease activity. New
erosions appeared in 33% of patients after 2 years. Several
baseline parameters were associated with radiographic
progression in the univariate analysis: shared epitope (SE)
homozygozity, HLA-DRB*04 alleles, female gender, he-
moglobin, erythrocyte sedimentation rate, and anticyclic
citrullinated peptide antibodies (anti-CCP). In the multivar-
iate analysis, female gender [odds ratio (OR) 5.5, 95%
confidence interval (CI): 1.1–28.2, p=0.04], DRB1*04
alleles (OR 3.1, 95% CI 1.1–9, p=0.03) and, marginally,
anti-CCP antibodies (OR 3.6, 95% CI 0.9–14.5, p=0.06),
were associated with progression. Female patients with
both DRB1*04 alleles and anti-CCP antibodies showed the
highest scores in radiographic progression. The presence,
but not the titer, of anti-CCP antibodies predicted progres-
sion. The positive predictive value of the multivariate
model for progression was only 53.9% whereas the
negative predictive value was 80.3%. In a series of early
RA patients treated with a structured algorithm using
DMARDs and very low doses of glucocorticoids, radio-
graphic progression was observed in one third of patients
after 2 years. Female gender, DRB1*04 alleles (rather than
the SE), and the presence of anti-CCP antibodies at
baseline (independently of the titer) were the most
important predictors of progression. The utility of these
parameters in clinical practice is limited by their relatively
low positive predictive value.
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Introduction
Rheumatoid arthritis (RA) is a systemic chronic inflammatory
disease of unknown etiology associated with progressive joint
destruction and disability, together with relevant social and
economics costs [1]. Radiographic joint damage is consid-
ered one of the most important outcome measures in RA [2],
with the erosive changes that appear early in the disease
course [3] being considered predictors of poor prognosis in
the long-term [4]. Current therapeutic strategies in RA are
directed at preventing progressive joint destruction [5].
The clinical course of RA is variable, and the rate of
radiographic progression differs between patients. Various
studies have attempted to identify prognostic factors of
radiographic progression in patients with early RA. These
studies have found that various factors, including serum
autoantibodies [rheumatoid factor (RF)] [6, 7], anticyclic
citrullinated peptide (anti-CCP) antibodies [8, 9], HLA-
DRB1 genotype [10, 11], or elevated inflammatory activity
[12] are associated with worse radiographic outcome,
although controversy remains, as there was no absolute
agreement between studies. However, in these studies,
patients were not treated with a standardized structured
therapeutic strategy, making it difficult to elucidate the
possible influence of the type of antirheumatic therapy on
the rate of radiographic progression. Recently, we presented
our preliminary data on a 1-year radiographic progression in
a cohort of early RA patients after the introduction of a
structured therapeutic algorithm with disease-modifying
antirheumatic drugs (DMARDs) and low doses of gluco-
corticoids in a clinical setting [13]. The present study
investigates the baseline prognostic factors of radiographic
progression in a series of 105 Spanish patients with early RA
2 years after the introduction of this therapeutic strategy.
Materials and methods
Patients Patients who fulfilled the American College of
Rheumatology (ACR, formerly the American Rheumatism
Association) [14] criteria for the classification of RA, with
symptoms of <24 months, were enrolled in this study. All
were outpatients attending the rheumatology units of the
Hospital Clinic of Barcelona or the Hospital Parc Tauli of
Sabadell between 1998 and 2003, and were followed for
2 years. Patients who were treated previously with DMARDs
or prednisone or equivalent at a dose of >10 mg/day were
excluded. The study was approved by the Hospital Clinic
ethics committee.
Study design We conducted a prospective open-label study
where all patients were treated according to a therapeutic
protocol, with early introduction of DMARDs using a step-
up approach. In all cases, intramuscular sodium aurothio-
malate at a dose of 50 mg/week (25 mg/week during the
first 2 weeks) was prescribed as the first-choice DMARD
together with methylprednisolone 4 mg/day. Nonsteroidal
anti-inflammatory drugs and intraarticular steroid therapy
were used according to clinical judgment. Methotrexate at
an increasing dose of 7.5 to 20 mg was begun if adverse
effects without clinical improvement or no ACR20
response were observed at month 6. If an ACR50 response
at 6 months was observed, gold salts were scheduled every
2–3 weeks, but if a patient had an ACR20 response but no
ACR50 response, combination therapy with sodium auro-
thiomalate and methotrexate was initiated. Glucocorticoid
therapy was tapered according to clinical judgment. After
the first year of therapy, patients were treated without an
established protocol algorithm and according to the criteria
of the treating physician, but with an aggressive approach
using other DMARDs in monotherapy or in combination in
cases with a poor response to previous DMARDs.
Biological therapy was initiated in a few cases in patients
with a poor response to DMARDs.
Disease activity was assessed at 0, 3, 6, 12, 18, and
24 months. At study entry, demographic characteristics,
disease duration, serum RF determined by nephelometry
(NV<25 UI/l), anti-CCP antibodies measured by a
second-generation ELISA test (Immunoscan RA, Euro-
diagnostica, distributed by Diasorin, Madrid, Spain; NV<
50 UI/l), and HLA-DRB1 genotype determined by direct
DNA sequencing were analyzed. At baseline, 6, 12, 18,
and 24 months, we recorded the following parameters:
pain using a visual analog scale (VAS), the 28 tender
and swollen joint count, patient and physician assessment
of disease status, the 28-joint disease activity score
(DAS28), functional status using the modified Health
Assessment Questionnaire (mHAQ) [15], hemoglobin,
erythrocyte sedimentation rate (ESR), and C-reactive
protein (CRP) determined by nephelometry.
Radiographic assessment Radiographies of hands and feet
were obtained at baseline and after 12 and 24 months of
follow-up. The modified Larsen method was used to
evaluate radiographic damage; 32 joints were assessed with
the scores ranging from 0 to 200; each wrist was considered
a unit and its score was multiplied by 5 [16]. An erosion
joint count (EJC), defined as the number of joints with any
cortical erosion out of the 32 joints evaluated, was also
done. All radiographs were read by the same observer (RS)
in chronological order. The minimal clinically important
difference was used as a measure of radiographic progres-
sion [17]. Using this approach, a change of two or more
units in the Larsen score was considered as indicative of
progression after 1 year in early RA. Therefore, in this
study, definite radiographic progression was defined as an
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increase of four or more units in the Larsen score between
baseline and 24 months. The appearance of new erosions
(increase in the EJC) was also evaluated.
Statistical analysis The statistical analysis was performed
using the STATA statistical program, version 8.2. The
outcome measure was radiographic progression measured
by the Larsen method, as previously defined. The univariate
analysis of categorical variables used the chi-square test or
Fisher’s exact test and continuous variables were assessed
with the Student t-test or the Mann–Whitney test, when
appropriate. For paired samples, the t-test or Wilcoxon test
were used. For multiple group comparisons, one-way
analysis of variance or the Kruskal–Wallis test was
performed. All marginally significant variables (p<0.25)
in the univariate analysis were entered into the multivariate
analysis (stepwise logistic regression model) as indepen-
dent variables. The sensitivity, specificity, and positive and
negative predictive values of the final multivariate model
were also analyzed. For all tests, p values less than or equal
to 0.05 were considered significant.
Intraobserver agreement in the radiographic Larsen score
was assessed with a k-statistic on 25 randomly chosen pairs
of hand and foot radiographs; the k value was 0.77
[confidence interval (CI) 0.61–0.93].
Results
One hundred and fifteen patients were initially enrolled.
Ten patients did not complete the 2-year follow-up for
varying reasons: irregular or lost follow-up (six patients),
death (two patients), transfer out (one patient), and doubts
about disease duration (one patient). The final cohort
included 105 patients whose hands and feet radiographs at
0 and 24 months were available in 100 patients (in 104
patients at baseline, in 97 patients at 1 year, and in 101 patients
at 2 years). Baseline characteristics of the 105 patients are
shown in Table 1. Eighty-one percent of the patients were
female. The majority of patients had RF and anti-CCP
antibodies in their sera. In 73 patients (69.5%) the disease
duration was <1 year. Most patients (75.7%) presented high
disease activity (DAS28>5.1) at study entry, which de-
creased significantly after 1 and 2 years (19.6 and 15.2%,
respectively, p<0.001). At 1 year, ACR20 and ACR50
responses were achieved by 73.3 and 44.8% of the patients,
respectively. After 2 years, the percentages of ACR 20 and
ACR50 responses were 73.3 and 55.2%, respectively.
European League Against Rheumatism (EULAR) response
(good or moderate) criteria were achieved by 78% of the
patients at month 12 and by 81.9% of the patients at
month 24 (Table 2). Drug treatment at 6, 12, and 24 months
is shown in Fig. 1. After 2 years, sodium aurothiomalate was
taken by 41 patients. The reasons for withdrawal of gold
were inefficacy (28 patients) or adverse events (22 patients),
mucocutaneous side-effects, 12 patients; proteinuria, 7
patients; and others, 3 patients. After 2 years, 62.5% of the
patients were still taking oral glucocorticoids at a mean daily
dose of methylprednisolone of 2.3±2.5 mg/day. During the
follow-up, 18 patients received DMARDs other than gold or
methotrexate and 10 patients received biological therapy; in
all but one of these patients, TNF-alpha blockers were
initiated during the second year of follow-up.
Radiographic outcome
Erosions were observed at study entry in 19 patients
(18.3%), in 28 patients (28,9%) at month 12, and in 45
patients (44.6%) at month 24. After 2 years, mean EJC and
Larsen scores increased from 0.4±0.9 to 1±1.4 and from
1.2±2.7 to 6.1±9.3, respectively. Two-year radiographic
progression occurred in 32 out of 100 patients (32%), as
previously defined. New hand or foot erosions were
observed in 33% of the patients.
Prognostic markers of radiographic progression
In the univariate analysis, the following clinical and
biological parameters were significantly associated with
Larsen radiographic progression: hemoglobin, ESR, female
gender, shared epitope (SE), SE homozygozity, HLA-
DRB1*04 genotype, and anti-CCP antibodies. The highest




Disease duration (months) 10±6.7
VAS pain (mm) 51.3±21.6
Patient’s global assessment (mm) 57.8±15.1
Physician global assessment (mm) 55.8±13.9
28-Tender joint count 10.1±5.9







RF + (%) 74.3
Anti-CCP2 + (%) 70.4
SE (%) 70.6
SE homozygozity (%) 20.6
HLA-DRB*04 (%) 44.1
Results are expressed in mean values±SD or percentages (%).
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odds ratios (OR) were observed with SE homozygozity,
female gender, anti-CCP antibodies, and HLA-DRB1*04
alleles. A marginal significance was also observed for RF
and mHAQ (Table 3).
In the multiple regression analysis, the final model
included only female gender (OR 5.5) and DRB1*04
alleles (OR 3.1) as independent factors associated with
Larsen radiographic progression. The presence of anti-CCP
antibodies was also marginally associated with progression
(OR 3.6, p=0.06) (Table 4). The sensitivity and specificity
of this multivariate model were 53.9 and 81.7%, respec-
tively, whereas the positive predictive value and the
negative predictive value were 56 and 80.3%, respectively.
To elucidate which combination of variables selected for
the multivariate model were associated with greater
radiographic Larsen progression, different combination
groups were analyzed. The mean change in Larsen score
was 8.7±12 in female patients with both anti-CCP (+) and
DRB1*04 (+) (n=25), 3±4.8 in female patients with anti-
CCP (+) and DRB1*04 (−) (n=23), and only 1.1±2
(p<0.01) in females with both anti-CCP (−) and DRB1*04
(−) (n=17). The other combination groups yielded an
insufficient sample size for analysis.
To analyze whether the titer of baseline anti-CCP
antibodies were relevant in determining radiographic
progression, we compared the values of these antibodies
in anti-CCP positive patients with and without Larsen
progression; the median values of anti-CCP antibodies in
patients with radiographic progression were not significant-
ly different to those of patients without progression
[628 UI/l (C25/C75, 247:1,600) vs 750 UI/l (C25/C75,
247:1,600), p=0.68].
Finally, when the EJC (evidence of one or more new
erosions after 2 years) was used as a criteria of radiographic
progression, only the presence of two copies of the SE
(p<0.05) and the presence of anti-CCP antibodies (p=0.05)
were significantly associated with progression.
Discussion
This study, together with other studies focusing on
progression of radiographic damage in early RA after the
introduction of DMARDs [6–10, 18, 19], clearly shows
that early introduction of a therapeutic strategy with
DMARDs in recent-onset RA improves clinical and
biological parameters of disease activity, but does not
prevent radiographic progression in a significant proportion
of patients. Patients with erosive disease increased from
18.3 to 44.6% and the Larsen score increased to a mean of
almost five points after 2 years. Larsen radiographic
progression was observed in 32% of patients, in spite of
the use of DMARDs and very low dose of glucocorticoids.
However, in our cohort of RA patients, more than half still
had nonerosive disease after 2 years of follow-up.
Our results are in agreement with those observed in the
prospective study by Combe et al. [18] in Mediterranean
patients with early RA, which found that, using the
modified Sharp–van der Heijde method and the smallest
statistical difference as the measure of progression, the rate
of progression was 41.3% after 3 years of DMARD
therapy. However, in this and other studies analyzing
prognostic factors of radiological progression in early RA
[18–21], patients were treated with different DMARDs
without a structured therapeutic strategy, making it difficult
to establish the possible influence of the antirheumatic drug
therapy on disease progression. It is known that the effects
Table 2 Clinical, biological,
and radiological characteristics,
drug therapy, and therapeutic
responses at study entry and
after 1 and 2 years of follow-up
in 105 early RA patients
Results are expressed in mean
values±SD or percentages (%).
Baseline 12 months 24 months
28-Tender joint count 10.1±5.9 3.5±4.7 2.7±4.1
28-Swollen joint count 8.3±4.1 2.6±3.3 2.1±3.5
DAS28 5.7±1 3.8±1.3 3.5±1.3
VAS pain (0–100 mm) 51.3±21.6 31.9±23.9 28.8±21.1
ESR (mm) 39.6±24.5 25.5±18.9 22.9±15.8
CRP (mg/dl) 2.8±2.9 1.3±1.6 1.2±1.5
mHAQ (0–3) 1±0.6 0.5±0.5 0.5±0.5
Erosion join count 0.4±0.9 0.8±1.5 1±1.4
Larsen score 1.2±2.7 3.5±6.7 6.1±9.3
ACR20 response (%) 73.3 73.3
ACR50 response (%) 44.8 55.2
EULAR response (%) 78 81.9
Good EULAR response (%) 35.2 48.6
Remission (DAS28<2.6) 0 23.5 32.4
Patients receiving I.M. gold (%) 60.8 38
Patients receiving oral steroids (%) 65.7 62.5
Patients receiving methotrexate (%) 36.1 46.6
Patients receiving anti-TNF-α (%) 1 9.5
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of different DMARDs on radiographic damage may differ,
even after an apparently similar clinical benefit [22]. In
contrast, our patients were treated with the same therapeutic
algorithm, with gold salts as the first DMARD and with
methotrexate in monotherapy or in combination when a
partial or no response was achieved or when there were
adverse events to gold. Although the use of aurothiomalate
in RA has declined significantly in recent years, its effects
on radiographic progression are well established and are
similar to those of methotrexate [23].
To our knowledge, there is only one reported study
focusing on radiographic progression in RA using a
structured therapeutic algorithm. In this study in an early
RA-based population and using hydroxychloroquine in
monotherapy as the first DMARD, with surprising results
on clinical efficacy, Goronzy et al. [24] found a prevalence
of radiographic progression (defined as the appearance off
new erosions) of 52% after 2 years, a higher figure than that
observed in our cohort (33%) using the same criteria. The
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23/ 13 § 11 ¶ 15
* Other DMARDs combined with methotrexate (MTX) different from gold 
** Leflunomide n=1  Infliximab n=1
§ Leflunomide n=1, Cyclosporine A n=4,  Infliximab n=5 , Etanercept n=1, Adalimumab n= 1, Hydroxichloroquine n=1
‡ Leflunomide n=1
¶ Leflunomide n=6, Leflunomide + Infliximab n= 2, Etanercept n=1, Cyclosporine A  n=1, Hydroxichloroquine n=1
Fig. 1 Drug therapies administered at 6, 12, and 24 months of follow-
up. *Other DMARDs combined with methotrexate (MTX) different
from gold. **Leflunomide n=1, infliximab n=1. §Leflunomide n=1,
cyclosporine A n=4, infliximab n=5, etanercept n=1, adalimumab n=
1, hydroxychloroquine n=1. ‡Leflunomide n=1. ¶Leflunomide n=6,
leflunomide + infliximab n=2, etanercept n=1, cyclosporine A n=1,
hydroxychloroquine n=1
Clin Rheumatol (2007) 26:1111–1118 1115
using antimalarials, which have a modest effect on the
prevention of structural damage [25], as the first-choice
DMARD, and the systematic use of very low doses of
glucocorticoids, which were shown to retard radiographic
progression [26], in our cohort, may explain the differences.
The present study clearly shows that there are several
prognostic factors of radiographic progression in early RA.
Three parameters emerged as the most important predictors
of progression: female gender, the HLA-DRB1 genotype
(DRB*04 allele and SE homozygozity rather than the SE
itself), and the presence of anti-CCP antibodies. Other
parameters often associated with worse radiographic out-
come, such as disease activity measured by clinical or
laboratory tests [12], were not found to be predictors of
radiographic damage. Women had greater radiographic
progression than men, as observed in other studies [20,
27], although others reports only found a nonsignificant
trend [18, 24]. We also found that patients with
HLADRB1*04 alleles or with SE homozygozity had
greater joint destruction than patients with other genotypes
[10, 11, 28]; this finding were also observed in Mediterra-
nean populations [29], where the course of RA is reported
to be more benign [30]. We have confirmed that the SE is
associated with significant joint damage progression only
when included in DRB1*04 alleles (or in the presence of
homozygozity), but not when included in other DRB1
genotypes such as DRB1*01 alleles.
RF is one of the most powerful predictors of joint
damage in early RA populations in most [6, 7, 10, 18, 21]
but not all studies [20]; however, in our study, although a
trend was evident with an OR of 3, a risk very similar to
those observed in other studies [31], the association with
progression was not significant. In contrast, the presence of
anti-CCP antibodies at baseline was associated with
radiographic progression. Recent studies of anti-CCP anti-
bodies have also shown that these antibodies are not only
very useful diagnostic markers of RA in patients with early
arthritis due to their high specificity [32], but are also
associated with poor radiological outcome in RA patients
[8, 9]. Recent reports confirm the prognostic significance of
these antibodies in early RA to be even greater than RF [33,
34]. Berglin et al. [35] reported that anti-CCP antibodies
detected in preclinical phases of RA predict a poor
radiographic outcome in early RA after 2 years of follow-
up, whereas RF does not. However, our results are in
contrast to those of our preliminary study [13] where anti-
CCP were not associated with greater progression after
1 year of follow up; the shorter follow up, the smaller
sample size, or the fact that the anti-CCP were determined
using a first generation ELISA technique (CCP1) in this
first study could explain this discrepancy. In fact, a recent
study demonstrated a higher value of anti-CCP2 antibodies
Table 3 Baseline variables at study entry in RA patients with and without radiographic progression (increase in Larsen score >4) at 2 years
Progression (n=32) No progression (n=68) OR 95% CI p value
Gender (% female) 93.8 75 5 1.0–23.1 0.04
Age (year) 55.1±12.3 55.2±16 0.99 0.97–1.02 0.97
Disease duration (months) 10.8±6.6 9.9±6.9 1.01 0.95–1.08 0.54
28-Tender joint count 10.1±5.5 10.1±6.2 0.99 0.93–11.07 0.99
28-Swollen joint count 7.3±4.2 8.9±4.1 0.90 0.80–1.01 0.08
DAS28 5.73±0.88 5.60±0.95 1.18 0.74–1.88 0.50
VAS pain (0–100 mm) 56.5±19.4 48.5±22.6 1.01 0.99–1.03 0.09
ESR (mm) 46.9±28 34.9±21.6 1.02 1.0–1.03 0.03
CRP (mg/dl) 3.3±3.2 2.6±2.9 1.07 0.93–1.23 0.29
Hemoglobin (mg/dl) 12±1.4 13.1±1.3 0.94 0.90–0.97 0.001
mHAQ (0–3) 1.1±0.5 0.9±0.6 2.15 0.96–4.8 0.06
RF + (%) 87.5 69 3.13 0.97–10.04 0.06
Anti-CCP + (%) 86.7 62 4 1.24–12.9 0.02
Erosion join count 0.4±1 0.4±0.7 1.01 0.64–1.59 0.97
Larsen score 1.7±3.7 1.1±2.2 1.07 0.92–1.24 0.35
SE (%) 74.2 63.6 2.97 1.0–8.7 0.05
SE-homozygous (%) 38.7 13.6 6.4 1.75–23.3 0.005
HLA-DRB*04 (%) 64.5 34.8 3.40 1.39–8.3 0.007
Results are expressed in mean values±SD or percentages (%).
Table 4 Stepwise logistic regression analysis of prognostic factors of
Larsen progression at 2 years
Coefficient SE OR 95% CI p value
Female gender 1.702 0.835 5.48 1.07–28.17 0.04
DRB1*04 (+) 1.147 0.536 3.15 1.10–9.00 0.03
Anti-CCP (+) 1.290 0.705 3.63 0.91–14.46 0.06
Constant −3.849
SE Standard error, OR odds ratio, 95% CI 95% confidence interval
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compared to anti-CCP1 antibodies in determining disease
progression [36]. It is interesting to note that the anti-CCP
antibody titer does not seem to be relevant in predicting
radiographic outcome: the median titers of anti-CCP anti-
bodies were not significantly different between anti-CCP-
positive patients with and without radiographic progression,
results that differ from a recent report where baseline values
of anti-CCP were higher in RA patients with a worse
radiographic outcome [35]. Methodological issues or the
use of a different ELISA kit may explain these differences.
Our study had some limitations, which includes the
relatively small sample size, the problem of the missing
values of some variables, inherent to this type of longitu-
dinal studies, and the short follow-up period. Although it
was thought that patients with erosive RA frequently
develop erosions during the first 2 years of the disease [3,
37], recent studies shown that erosions may develop for the
first time after 2 years of disease evolution [38]. Therefore,
it is not unlikely that some of the patients with erosive
disease in our studies could develop erosions and joint
damage in the near future. In addition, a small percentage
of patients received TNF-blocking agents during the follow
up. The potential of these agents in delaying structural
damage is recognized [39] and this may have had some
influence on the degree of disease progression in the
present study. However, the small number of cases treated
(ten patients, all but one during the second year, and with
evidence of radiographic progression in three) suggests that
these agents had no influence on our overall results.
Although some baseline parameters were associated with
greater radiological progression in this and other studies of
patients with early RA treated early with DMARDs, it is
difficult to use these parameters in normal clinical practice
to provide a differentiated therapeutic strategy, mainly
because their predictive value for progressive disease is
far from 100%. In our study, the multivariate model that
included female gender, the presence of HLA-DRB1*04
alleles and anti-CCP, showed a relatively low sensitivity
and positive predictive value for detecting radiological
progression. However, the percentages for specificity and
negative predictive value were higher (around 80%),
suggesting that it may be the absence of these parameters
which could have greater clinical relevance in predicting
patients who will not suffer disease progression. In our
cohort of female patients with RA, those with positive
HLA-DRB1*04 and anti-CCP had a much greater rate of
radiological progression than those with negative DRB1*04
and anti-CCP. A recent study found that the association of
HLA-DRB1*04 and anti-CCP also resulted in greater
disease progression compared with cases with one or
neither of these factors [40].
In conclusion, in one third of patients with early RA treated
with DMARDs and very low doses of glucocorticoids,
significant radiographic progression was observed after
2 years, despite a systematic scheduled therapeutic strategy.
Female gender, the SE included in HLA-DRB1*04 alleles (or
with homozygozity), and the presence of anti-CCP antibodies
at baseline (rather than the titer) were the most significant
predictors of radiographic progression. However, in our
opinion, the positive predictive value of these parameters is
probably not high enough to advise its use in clinical practice
to predict progression or to recommend more aggressive
therapeutic approaches in these patients.
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